News | August 13, 2024
Supriya Lifescience reports robust Q1 FY25 results with 21.7% revenue growth
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
The fresh funds will be used to enhance customer relationships, expand operations and develop state-of-the-art service
These results add to the growing body of evidence indicating a single dose of ABRYSVO provides strong immune protection against outcomes caused by RSV
This project is supported by the Irish Government through IDA Ireland
Morepen Labs successfully raised Rs. 200 Crore through QIP
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
The campaign targets 63 endemic districts across Bihar, Jharkhand, Karnataka, Odisha, Telangana, and Uttar Pradesh
Subscribe To Our Newsletter & Stay Updated
